All In MedTech

Device Trial Radar · NCT02730663

A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'

A Prospective, Multi-center, Single Arm, Non-inferiority, Open-label, Pivotal Study to Evaluate the Effectiveness and Safety of EUS -Guided Transluminal Drainage With 'Niti-S SPAXUS Stent' for the Treatment of Pancreatic Pseudocyst

Last checked: Nov 20, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Mar 21, 2016

Primary completion

Jun 14, 2017

Study completion Jun 14, 2017

Sponsor

Lead sponsor
Taewoong Medical Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Apr 6, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of endoscopic ultrasound (EUS)-guided transluminal drainage with 'Niti-S SPAXUS Stent' for the treatment of pancreatic pseudocyst.

Conditions

  • Pancreatic Pseudocyst

Interventions

  • Niti-S SPAXUS StentDevice

    Endoscopic Ultrasound-Guided Transluminal drainage

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical SuccessTime frame: at stent removal (Day 30 or Day 60)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Kyungpook National University Medical Center

    Daegu, South Korea

  • Chonbook National University Hospital

    Jeonju, South Korea

  • Asan Medical Center

    Seoul, South Korea

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.